A Brief Report of 10-Year Trends in the Use of Stereotactic Lung Radiotherapy at a Dutch Academic Medical Center  by Peguret, Nicolas et al.
114 Journal of Thoracic Oncology ®  •  Volume 9, Number 1, January 2014
This report describes clinical trends in the use of stereotactic lung 
radiotherapy in a large single-institution program over the last 10 years. 
Changes in patient, tumor, and treatment characteristics are highlighted.
(J Thorac Oncol. 2014;9: 114–117)
Stereotactic body radiotherapy (SBRT) typically consists of a relatively small number of high-dose fractions deliv-
ered to extracranial targets and reports of its use date back 
to the early 1990s.1–3 Since then, it has become accepted as 
an effective treatment for patients with medically inoperable 
early-stage peripheral non–small-cell lung cancer (NSCLC) 
and its introduction throughout The Netherlands has been 
associated with improvements in population-based outcomes 
for early-stage NSCLC.4–6 Despite the fact that follow-up has 
been of limited duration, and lower rates of pathological con-
firmation of malignancy have been obtained in some SBRT 
series, recent analyses suggest that SBRT may achieve local 
and regional control rates that are comparable with surgery in 
early-stage NSCLC.7 High local control rates have also been 
reported for lung metastases.8 Our department started lung 
SBRT in 2003. This report investigates the effect of a decade 
of increasing experience, evolving evidence, and the increas-
ingly widespread adoption of lung SBRT on the patterns of 
practice in a single Dutch academic medical center.
PATIENTS AND METHODS
Details of patients with a clinical or histological diag-
nosis of early-stage NSCLC, or lung metastases treated with 
lung SBRT are routinely documented in an institutional 
database. This was retrospectively analyzed using five approx-
imately equal periods: 1=April 2003–March 2005, 2=April 
2005–March 2007, 3=April 2007–March 2009, 4= April 
2009–March 2011, and 5=April 2011–February 2013. Of 
1082 patients, 989 with a pathologic (histologic or cytologic) 
or clinical diagnosis of early-stage NSCLC (T1-2N0M0) 
or metastatic lung disease were included in this report. We 
excluded 8.6% of patients (93 of 1082) for reasons such as 
more advanced disease, treatment with nonstandard doses 
(n=5, including those treated with a single fraction), reirra-
diation for in-field recurrence, a diagnosis of small-cell lung 
cancer or patients with no recorded stage. Where a patient 
had undergone more than one course of treatment, data from 
the first course were used in this report. If more than one 
lesion was irradiated in this course (this was the case in <7% 
courses), data from the index lesion in the database were used. 
As described previously,4 patients were treated by using a risk-
adapted strategy in which the prescription dose fractionation 
was determined by tumor size and proximity to critical struc-
tures. In brief, three fractions were typically used for periph-
eral T1 tumors, five fractions for peripheral T2 tumors or T1-2 
tumors in broad contact with the chest wall, and eight frac-
tions for central tumors (e.g., close to mediastinum or central 
airways, consistent with the definition in Radiation Therapy 
Oncology Group (RTOG) 0236, or where the target volume 
was in contact with/overlapping pericardium)9,10 or those 
considered too large for five fractions. Twelve fractions were 
introduced more recently for progressively bigger and more 
central target volumes (e.g., mediastinal extension). Current 
dose-fractionation schedules are as follows: 3 × 18 Gray (Gy), 
5 × 11Gy, 8 × 7.5Gy, and 12 × 5Gy. All routinely prescribed to 
the 80% isodose, which should cover at least 95% of the plan-
ning target volume (PTV), with a maximum dose in the PTV of 
140% of the prescribed dose. These schemes have a biological 
effective dose for tumor effect (using α/β=10) of 151 Gy10, 
116 Gy10, 105Gy10, and 90 Gy10, respectively. Patients have 
routinely undergone four-dimensional computed tomogra-
phy (CT) scan for treatment planning. Before 2008, patients 
were treated with eight to 12 fixed non–coplanar conformal 
beams on the Novalis platform (Brainlab AG, Feldkirchen, 
Germany) with patient positioning based on stereoscopic 
spine imaging with ExacTrac (Brainlab AG). This was subse-
quently replaced by a combination of volumetric modulated 
arc therapy (VMAT; RapidArc, Varian Medical Systems, Palo 
Alto, CA) and online cone-beam CT) tumor-based positioning 
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on the Novalis Tx™ (Brainlab and Varian Medical Systems) 
and TrueBeam™ (Varian Medical Systems) platforms. Since 
the VMAT treatment planning system involved a change in the 
dose calculation algorithm (from pencil beam based iPlan® 
to the Analytic Anisotropic Algorithm in Eclipse™) the dose 
per fraction was modified and is currently as described above.
The report focuses on patient, tumor and treatment 
delivery characteristics in order to describe trends in patient 
care and clinical practice. The purpose was not to describe 
clinical outcomes, which have recently been reported for 
a large patient group,4 nor to conduct a longitudinal analy-
sis, both of which are beyond the scope of this brief report. 
Detailed statistics have not been applied, as the goal was to 
describe broad changes in clinical practice.
RESulTS
Patient characteristics
Data from 989 patients treated with lung SBRT between 
April 2003 and February 2013 forms the basis of this report. 
Of these, 900 patients had a clinical or pathologic diagnosis 
of early-stage NSCLC (pathological confirmation in 27% and 
42.9% in the first and last periods, respectively) and 89 had 
metastatic lung disease (pathological confirmation in 75% and 
42.9% in the first and last periods, respectively). Computed 
tomography and fluorodeoxyglucose positron emission tomog-
raphy evaluation were a routine part of the clinical diagnostic 
algorithm. In patients with metastatic lung disease the most 
commonly known primary tumors were colorectal, lung, and 
sarcoma. The current median follow-up (to last contact or date 
of death, in years) for all patients, and those considered medi-
cally operable, was 2.8 of 5.5, 3.5 of 4.9, 2.9 of 4, 1.7 of 2, and 
0.6 of 0.8 years in the periods 1 to 5 respectively. Analyzed 
over the whole study period, 93.2% of patients had one lesion, 
6.3% had two, and 0.5% had more than two treated simultane-
ously. Table 1 summarizes patient, tumor, and treatment char-
acteristics during the five time periods. There was an almost 
fivefold increase in the number of patients treated from period 
1 to 4. Median patient age fell from 81 years (range, 57–93) in 
the first period to 71 years (range, 44–93) in the final period. 
Median age of all patients with metastatic disease was 66 
years (range, 41–87) compared with 79 years (range, 46–97) 
for those with NSCLC. Although there was a trend toward an 
increase in the proportion of fitter patients (performance sta-
tus [PS] 0–1) in recent years (59.7% and 65.5% of patients in 
periods 1 and 2, respectively, compared with 71.4% and 78% 
in periods 4 and 5 respectively), the proportion of patients con-
sidered medically inoperable was relatively stable at 80.6%, 
71.1%, 76.9%, 79.1%, and 82% for periods 1 to 5, respectively. 
Overall, 67.4% of patients had PS 0 to 1 (0.2% missing data); 
their median age was 77 years; 27.7% were considered medi-
cally operable; 11.2% had SBRT for metastatic disease, and 
38.5% had pathologic proof of malignancy. For those with PS 2 
to 3 (32.6%) the median age was 79 years; 4.6% had metastatic 
lung disease and 35.6% had a pathologic diagnosis. There 
were 221 patients (22.3%) classified as medically operable; 
median values were age = 78.4 years, Charlson Comorbidity 
Index (CCI)=2 (8.1% missing data), forced expiratory volume 
in 1 second (FEV1) = 2.07 (8.1% missing), and PS=1. In 
comparison, there were 768 medically inoperable patients 
(77.7%) with corresponding median age = 75.8 years, CCI = 3 
(10.9% missing), FEV1=1.60 (15.8% missing), and PS=1.
Tumor Characteristics
Over time, the general trend for all treatments was 
toward a reduction in median tumor diameter (Table 1). 
Median size of metastatic and primary tumors was 20 and 
27 mm, respectively. Median tumor diameter for three-, five-, 
eight-, and 12-fraction treatments was 19, 32, 34, and 41 mm, 
respectively. On average, there were about four times as many 
peripheral as central tumors throughout the study period 
(Table 1), with the majority of the latter (57.2%) treated in 
eight fractions. The proportion of patients with proven malig-
nancy increased between the first and last periods, rising from 
29.6% to 40.9% in medically inoperable patients and from 
30.8% to 51.7% in those considered medically operable. The 
ratio of patients with or without a pathologic diagnosis has 
been steady at about 40:60 over the last 6 years (Table 1). A 
trend was observed toward an increasing number of metastatic 
lesions being treated over time (6.0% in the first period, 10% 
in the fourth period, and 21.7% in last period).
Treatment Characteristics
Although the majority of treatments were delivered with 
three or five fractions throughout the study period, use of eight 
or 12 fractions increased during the last 4 years (Table 1). A 
total of 274 of 332 (82.5%) three-fraction treatments were 
for T1N0M0 tumors, compared with 149 of 402 (37.1%), 77 
of 217 (35.5%), and nine of 38 (23.7%) of five, eight, and 
12 fractions, respectively. Central tumors accounted for 115 
of 217 (53%) and 30 of 38 (78.9%) of eight- and 12-frac-
tion treatments, respectively. Whereas the majority of eight-
fraction treatments were initially given for central tumors, the 
proportion of peripheral tumors treated with eight fractions 
increased substantially in the last 4 years, to the point where 
it represented the majority (58% and 65% in periods 4 and 
5). Non–coplanar fixed conformal beams with spine-based 
ExacTrac image guidance were used to treat 51.7% of all 
patients and VMAT with tumor-based cone-beam CT image 
guidance was used for 48.3%. VMAT was used for 92.8% and 
100% of treatments in periods 4 and 5, respectively.
DISCuSSION
Although there is a large body of published literature 
dealing with lung SBRT outcomes, trends in the clinical use of 
lung SBRT have not been so well described. Although this is a 
single-center study, the sample size is large, which minimizes 
the impact of possible inaccuracies in individual data points, 
and the consistency of the treatment paradigm and decision 
making facilitates the detection of trends. Despite the increas-
ing number of radiotherapy departments offering lung SBRT 
in The Netherlands, now approximately two thirds of all cen-
ters, a steady increase in patient volume was observed during 
the first 8 years. This would be in keeping with the introduction 
and diffusion of this new technique into routine clinical prac-
tice, and the tendency to treat patients who might previously 
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have gone untreated.5 Although period 5 was slightly shorter 
than the others, the reduction in patients treated would be con-
sistent with the widespread national availability of peripheral 
lung SBRT. The stable percentage of patients with PS of 2 or 
better is in keeping with the consistent application of institu-
tional selection criteria by the tumor boards. The lower median 
CCI and higher FEV1 in patients classified as medically oper-
able also support consistency in decision making. The trend 
toward younger and fitter patients coincides with the increase 
in patients being treated for metastatic disease.
Despite the proportion of good PS (0 - 1) among patients 
and the trend toward younger patients, the majority are still 
considered to be medically inoperable. In addition, the num-
ber with pathologic proof of malignancy remains a minor-
ity.11 The decision to obtain a pathologic diagnosis will vary 
among patients. The multidisciplinary tumor board makes an 
assessment of the risks and benefits of invasive diagnostic 
procedures and takes into account the high probability of 
malignancy in patients with a growing, metabolically active 
lesion in a country with a low incidence of benign fluorode-
oxyglucose positron emission tomography positive lung nod-
ules.12 The predominance of peripheral lesions being treated 
reflects the initial evidence base supporting lung SBRT for 
such lesions.9 It is therefore noteworthy that the proportion 
of treatments classified as central has remained relatively 
stable from the beginning of the program. The concerns 
about increased toxicity with central lung SBRT were proac-
tively addressed at our center by implementing risk-adapted 
dose-fractionation schedules and regularly evaluating out-
comes.10 With increasing experience, as SBRT was used to 
treat larger and more central tumors, a 12-fraction scheme 
was introduced as an extension of the risk-adapted protocol. 
An appropriate level of caution is needed when treating cen-
tral, larger, and multiple tumors as normal organ constraints 
are less well established.13 The results of the prospective mul-
ticenter phase I/II RTOG 0813 study for central tumors are 
currently awaited. The qualitative reduction in median tumor 
diameter has coincided with a trend to treat more metastatic 
lesions and with the growing interest in using SBRT to treat 
patients with low-volume metastatic disease.14 The shift to 
using VMAT reflects the emergence of new technology that 
may help increase the efficiency of treatment.15
In summary, we have observed longitudinal trends in 
patient number, age, performance status, treatment indication, 
tumor size, dose fractionation, technology, and technique over 
the last 10 years of lung SBRT in routine clinical practice. 
With growing numbers of elderly patients with early-stage 
NSCLC and changing paradigms in the management of meta-
static disease, this type of data may be useful for radiotherapy 
services planning.
TABlE 1.  Patient, Tumor and Treatment Characteristics during Successive 2-Year Periods between April 2003 and February 
2013
Period 2003–05 2005–07 2007–09 2009–11 2011–13
Patients Patients Number  
(% of total)
67 (6.8) 180 (18.2) 260 (26.3) 321 (32.5) 161 (16.3)
Age (yrs) Median (range) 81 (57–93) 81 ((55- 97) 79 (46–97) 77 (41–96) 71 (44–93)
WHO performance status (%)a 0 11.9 12.2 9.2 15.9 24.5
1 47.8 53.3 50 55.5 53.5
2 38.8 28.9 35.4 24.9 18.9
3 1.5 5.6 5.4 3.7 3.1
Tumor Location (%) Peripheral 83.6 75.6 84.2 77.9 78.9
Central 14.9 22.2 15.4 20.6 19.9
Both 1.5 2.2 0.4 1.6 1.2
Histology or cytology (%) No 70.1 66.1 60.0 63.2 57.1
Yes 29.9 33.9 40.0 36.8 42.9
Stage (% in each period) T1N0M0 38.8 56.1 54.6 50.5 48.4
T2N0M0 55.2 39.4 41.5 39.6 29.8
M1 6.0 4.5 3.9 10 21.7
Treatment Fractions (% in each period) 3 46.3 38.3 38.5 27.7 26.7
5 41.8 46.7 40.8 39.9 34.8
8 11.9 15.0 20.8 27.4 24.8
12 NA NA NA 5.0 13.7
Fraction number and tumor diameter 
(mm): median (range)
3 20 (11–36) 20 (10–34) 19 (10–55) 19 (7–37) 14 (5–26)
5 37 (13–58) 32 (15–80) 34 (9–107) 31 (7–61) 28 (7–58)
8 37 (25–56) 35 (15–69) 35 (14–80) 34 (10–89) 28 (10–75)
12 NA NA NA 53 (15–85) 37 (12–68)
Periods: 1=April 2003–March 2005; 2=April 2005–March 2007; 3=April 2007–March 2009; 4=April 2009–March 2011; 5=April 2011–February 2013. 
aNo PS for two patients in period 5.
NA=not applicable (12 fractions not yet introduced); WHO=World Health Organization.
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